ORLYNVAH is safe and well tolerated1-3
The most common adverse reactions reported were gastrointestinal side effects, with the majority being mild in patients taking ORLYNVAH during clinical studies.
Most common adverse reactions (≥ 2%)
Adverse Reaction | ORLYNVAH N=1932 | Amoxicillin/ Clavulanate N=1107 | Ciprofloxacin N=822 |
|---|---|---|---|
| Diarrhea (n) | 10% (194) | 4% (45) | 3% (21) |
| Nausea (n) | 4% (80) | 3% (32) | 4% (30) |
| Vulvovaginal mycotic infection (n) | 2% (46) | 1% (13) | 1% (7) |
| Headache (n) | 2% (42) | 2% (17) | 2% (18) |
| Vomiting (n) | 2% (29) | 0.4% (4) | 1% (11) |
ONLY0.3%
experienced serious adverse reactions
Only 0.3% (6/1932) of patients treated with ORLYNVAH experienced serious adverse reactions1
ONLY1%
discontinued treatment
Only 1% (21/1932) of patients treated with ORLYNVAH discontinued treatment1
The most commonly reported adverse reactions leading to discontinuation of ORLYNVAH were nausea (6/1932; 0.3%), diarrhea (5/1932; 0.3%), as well as abdominal pain, gastroesophageal reflux disease, vomiting, and dizziness, each 0.2% (3/1932)1
Consistent clinical response
Demonstrated clinical efficacy against amoxicillin/clavulanate in a Phase 3 clinical trial1,3
Convenient, at-home dosing
A one pill, twice-daily, 5-day oral treatment1